# Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A

## TL;DR

Giant cell tumor of bone is a complex tumor driven by H3F3A mutations, impacting diagnosis and treatment through epigenetic and microenvironmental mechanisms.

## Contribution

This review highlights how H3F3A mutations reshape understanding of GCTB biology and treatment strategies.

## Key findings

- H3F3A p.G34 mutations drive GCTB through dysregulated RANKL signaling and chromatin changes.
- Denosumab treatment alters tumor morphology and promotes bone formation but long-term outcomes remain uncertain.
- GCTB serves as a model for epigenetically driven bone tumors influenced by tumor-microenvironment interactions.

## Abstract

Giant cell tumor of bone (GCTB) is a distinctive, intermediate-grade primary bone neoplasm defined by a neoplastic mesenchymal stromal compartment and a prominent osteoclast-rich microenvironment. Although histologically benign, GCTB is clinically consequential due to its locally destructive behavior, propensity for recurrence, and rare capacity for metastasis and malignant transformation. Over the past decade, the identification of recurrent H3F3A p.G34 mutations has fundamentally reshaped the understanding of GCTB pathogenesis, establishing the stromal cell as the true neoplastic driver and positioning the tumor as a paradigmatic epigenetically driven osteolytic disease. This narrative review focus on biology, pathophysiology, and histopathology in the era of H3F3A. H3F3A-mutant stromal cells orchestrate pathological osteoclastogenesis through dysregulated RANKL signaling and chromatin reprogramming, giving rise to the characteristic cellular admixture of osteoclast-type giant cells, mononuclear histiocytic cells, and neoplastic stromal elements. The targeted inhibition of osteoclast activity with denosumab has transformed clinical management, inducing profound morphological changes and bone formation. However, its long-term impact on local control, recurrence patterns, and malignant progression remains unclear. Collectively, GCTB exemplifies a molecularly defined bone tumor in which advances in epigenetic biology and tumor–microenvironment interactions have directly influenced diagnostic practice and therapeutic strategy. Ongoing challenges include refining risk stratification, optimizing treatment sequencing, and clarifying the biological consequences of sustained osteoclast suppression.